Notice 17 Mar 2025 regulations, grants, funding, biomedical research, nih, health

🎓NIH Announces Closed Meetings for Grant Application Reviews

The National Institute of General Medical Sciences has announced closed meetings to review grant applications for research excellence programs, including the SuRE and SBIR/STTR initiatives. These meetings, which are closed to the public due to confidentiality concerns, are essential for assessing funding opportunities that support biomedical research and innovation.

Learn More
Notice 17 Mar 2025 grants, nih, health, research, meeting, business opportunities

💼Notice of NIH Grant Review Meeting by Heart, Lung, and Blood Institute

The National Heart, Lung, and Blood Institute announces a closed meeting to review grant applications. The meeting, scheduled for April 22, 2025, will evaluate confidential trade secrets and personal information, ensuring privacy during discussions on significant health research funding. Contact details are provided for further inquiries.

Learn More
Notice 17 Mar 2025 grants, funding, nih, health, research, meeting, federal advisory

💼Notice of Grant Review Meeting by National Institute of Allergy and Infectious Diseases

The Department of Health and Human Services announces a closed meeting of the National Institute of Allergy and Infectious Diseases Special Emphasis Panel to evaluate grant applications. The session, which includes discussions on confidential trade secrets and individual privacy, will be conducted via video assistance.

Learn More
Notice 17 Mar 2025 grants, health, funding opportunities, national institutes of health, drug research

💊National Institute on Drug Abuse

The National Institute on Drug Abuse announces closed meetings to review grant applications related to drug abuse research. These meetings focus on evaluating various research proposals and initiatives, including medication development and chemical countermeasures for opioid exposure. The discussions aim to advance scientific research and innovation in drug-related fields.

Learn More
Notice 14 Mar 2025 compliance, regulation, fda, health, pharmaceutical, drug approvals

💊FDA Withdraws Approval of Eight Drug Applications

The Food and Drug Administration (FDA or Agency) is withdrawing approval of eight abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Learn More
Notice 14 Mar 2025 compliance, healthcare, regulation, government, health, legal

⚖️Overview of HHS Office of General Counsel's Organization and Authority

This document revises and restates the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Office of the General Counsel (OGC). Issuance of this Statement of Organization rescinds all prior Statements of Organization.

Learn More
Notice 14 Mar 2025 regulatory compliance, pharmaceuticals, fda, health, drug approval

💊FDA Withdraws Approval of Abbreviated New Drug Applications

The Food and Drug Administration (FDA or Agency) is withdrawing approval of four abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Learn More
Notice 13 Mar 2025 nih, health, grant applications, research funding, biomedical, regulatory meetings

💰NIH Grant Review Meetings

The Department of Health and Human Services announces closed meetings by the Center for Scientific Review to evaluate grant applications. These meetings will assess key topics in various biomedical fields and occur virtually, aiming to facilitate funding for innovative research projects and advancements in health sciences.

Learn More
Notice 13 Mar 2025 compliance, fda, debarment, health, sanctions, drug regulation, legal

⚖️Implications of John Kosolcharoen's FDA Debarment Order

The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring John Warrington Kosolcharoen from providing services in any capacity to a person that has an approved or pending drug product application including, but not limited to, a biologics license application (BLA). FDA bases this order on a finding that Mr. Kosolcharoen was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Mr. Kosolcharoen was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of December 26, 2024 (30 days after receipt of the notice), Mr. Kosolcharoen has not responded. Mr. Kosolcharoen's failure to respond and request a hearing constitutes a waiver of Mr. Kosolcharoen's right to a hearing concerning this matter.

Learn More
Notice 12 Mar 2025 grants, funding, nih, health, research, neuroscience, bioengineering

🧪Upcoming Closed Meetings for Grant Evaluations at NIH

The Department of Health and Human Services announces closed meetings for the Center for Scientific Review to evaluate grant applications in various scientific domains. The meetings are aimed at fostering advancements in health and bioengineering through collaboration, while ensuring that sensitive information remains confidential.

Learn More